Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $13.6 million.

  • Tarsus Pharmaceuticals' Accumulated Expenses rose 1966.45% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 1966.45%. This contributed to the annual value of $15.8 million for FY2024, which is 1946.39% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Accumulated Expenses stood at $13.6 million, which was up 1966.45% from $11.6 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Accumulated Expenses ranged from a high of $15.8 million in Q4 2024 and a low of $685000.0 during Q1 2021
  • Moreover, its 5-year median value for Accumulated Expenses was $5.5 million (2022), whereas its average is $6.8 million.
  • In the last 5 years, Tarsus Pharmaceuticals' Accumulated Expenses skyrocketed by 33192.31% in 2021 and then surged by 1946.39% in 2024.
  • Tarsus Pharmaceuticals' Accumulated Expenses (Quarter) stood at $2.8 million in 2021, then surged by 97.25% to $5.5 million in 2022, then skyrocketed by 139.99% to $13.2 million in 2023, then grew by 19.46% to $15.8 million in 2024, then dropped by 14.35% to $13.6 million in 2025.
  • Its last three reported values are $13.6 million in Q3 2025, $11.6 million for Q2 2025, and $9.9 million during Q1 2025.